Cryoport Future Growth

Future criteria checks 0/6

Cryoport is forecast to grow earnings and revenue by 51.9% and 7.5% per annum respectively. EPS is expected to grow by 54.2% per annum. Return on equity is forecast to be -10.5% in 3 years.

Key information

51.9%

Earnings growth rate

54.2%

EPS growth rate

Life Sciences earnings growth18.4%
Revenue growth rate7.5%
Future return on equity-10.5%
Analyst coverage

Good

Last updated18 Nov 2024

Recent future growth updates

Recent updates

Is Cryoport (NASDAQ:CYRX) A Risky Investment?

Nov 06
Is Cryoport (NASDAQ:CYRX) A Risky Investment?

The Market Lifts Cryoport, Inc. (NASDAQ:CYRX) Shares 36% But It Can Do More

Aug 09
The Market Lifts Cryoport, Inc. (NASDAQ:CYRX) Shares 36% But It Can Do More

Health Check: How Prudently Does Cryoport (NASDAQ:CYRX) Use Debt?

Jul 22
Health Check: How Prudently Does Cryoport (NASDAQ:CYRX) Use Debt?

Slammed 28% Cryoport, Inc. (NASDAQ:CYRX) Screens Well Here But There Might Be A Catch

Jun 25
Slammed 28% Cryoport, Inc. (NASDAQ:CYRX) Screens Well Here But There Might Be A Catch

Potential Upside For Cryoport, Inc. (NASDAQ:CYRX) Not Without Risk

Apr 15
Potential Upside For Cryoport, Inc. (NASDAQ:CYRX) Not Without Risk

Cryoport, Inc. (NASDAQ:CYRX) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 15
Cryoport, Inc. (NASDAQ:CYRX) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Cryoport Tanks On Chilling Results And Bad Decisions

Mar 14

Is Cryoport (NASDAQ:CYRX) Using Debt In A Risky Way?

Mar 10
Is Cryoport (NASDAQ:CYRX) Using Debt In A Risky Way?

Fewer Investors Than Expected Jumping On Cryoport, Inc. (NASDAQ:CYRX)

Jan 15
Fewer Investors Than Expected Jumping On Cryoport, Inc. (NASDAQ:CYRX)

Health Check: How Prudently Does Cryoport (NASDAQ:CYRX) Use Debt?

Oct 06
Health Check: How Prudently Does Cryoport (NASDAQ:CYRX) Use Debt?

Downgrade: Here's How Analysts See Cryoport, Inc. (NASDAQ:CYRX) Performing In The Near Term

Jul 23
Downgrade: Here's How Analysts See Cryoport, Inc. (NASDAQ:CYRX) Performing In The Near Term

Cryoport, Inc.'s (NASDAQ:CYRX) Subdued P/S Might Signal An Opportunity

Jul 12
Cryoport, Inc.'s (NASDAQ:CYRX) Subdued P/S Might Signal An Opportunity

Is Cryoport (NASDAQ:CYRX) A Risky Investment?

Jun 13
Is Cryoport (NASDAQ:CYRX) A Risky Investment?

Cryoport, Inc.'s (NASDAQ:CYRX) Intrinsic Value Is Potentially 96% Above Its Share Price

Mar 06
Cryoport, Inc.'s (NASDAQ:CYRX) Intrinsic Value Is Potentially 96% Above Its Share Price

Cryoport, Inc. (NASDAQ:CYRX) Analysts Just Cut Their EPS Forecasts Substantially

Nov 07
Cryoport, Inc. (NASDAQ:CYRX) Analysts Just Cut Their EPS Forecasts Substantially

Is Cryoport (NASDAQ:CYRX) Using Debt In A Risky Way?

Sep 23
Is Cryoport (NASDAQ:CYRX) Using Debt In A Risky Way?

Cryoport: A Rare Investing Opportunity

Sep 22

Cryoport enters into strategic relationship with Takeda's BioLife Plasma Services

Sep 08

Cryoport: Rapid Growth Is Great, But Shares Look Overpriced

Jul 30

Cryoport: To Resume Aggressive Growth

May 11

Cryoport: An Industry Leader Basking In Industry Tailwinds

Apr 15

Cryoport: Risky Investment With Upside Potential

Apr 01

Cryoport: More Growth Going Into New Year 2022

Dec 29

Is Cryoport, Inc. (NASDAQ:CYRX) Trading At A 49% Discount?

Dec 05
Is Cryoport, Inc. (NASDAQ:CYRX) Trading At A 49% Discount?

Earnings and Revenue Growth Forecasts

NasdaqCM:CYRX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026266-47-18107
12/31/2025246-51-30-59
12/31/2024228-88-23-310
9/30/2024226-166-36-8N/A
6/30/2024226-181-45-11N/A
3/31/2024225-121-46-7N/A
12/31/2023233-108-46-1N/A
9/30/2023236-55-410N/A
6/30/2023241-47-323N/A
3/31/2023248-38-290N/A
12/31/2022237-45-26-2N/A
9/30/2022233-296-27-3N/A
6/30/2022230-297-235N/A
3/31/2022222-293-1215N/A
12/31/2021223-284-178N/A
9/30/2021215-76-25-4N/A
6/30/2021169-78-32-18N/A
3/31/2021122-77-34-22N/A
12/31/202079-75-25-15N/A
9/30/202040-22-11-4N/A
6/30/202038-23-60N/A
3/31/202037-20-50N/A
12/31/201934-18-7-1N/A
9/30/201930-20-8-2N/A
6/30/201926-9-7-2N/A
3/31/201922-9-6-2N/A
12/31/201820-10-6-3N/A
9/30/201817-10-7-4N/A
6/30/201815-9N/A-5N/A
3/31/201813-9N/A-4N/A
12/31/201712-8N/A-4N/A
9/30/201711-10N/A-3N/A
6/30/201710-10N/A-4N/A
3/31/20179-12N/A-5N/A
12/31/20168-13N/A-6N/A
9/30/20167-12N/A-6N/A
6/30/20166-12N/A-6N/A
3/31/20166-15N/A-6N/A
12/31/20156-16N/A-6N/A
9/30/20155-15N/A-5N/A
6/30/20154-16N/A-5N/A
3/31/20154-12N/A-4N/A
12/31/20144-10N/A-4N/A
9/30/20143-10N/A-4N/A
6/30/20143-21N/A-4N/A
3/31/20143-20N/A-4N/A
12/31/20132-20N/A-4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CYRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CYRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CYRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CYRX's revenue (7.5% per year) is forecast to grow slower than the US market (8.9% per year).

High Growth Revenue: CYRX's revenue (7.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CYRX is forecast to be unprofitable in 3 years.


Discover growth companies